Plasmodium parasite proteins

Plasmodium parasite proteins encompass a diverse array of essential molecules within the Plasmodium genus, primarily P. falciparum, which are critical for the parasite's survival, replication, and pathogenesis in the human host (Microbiology Journal, NIH). These proteins serve as the primary targets for antimalarial chemotherapy and vaccine development, spanning various biological processes such as hemoglobin degradation in the food vacuole, de novo folate and pyrimidine biosynthesis, and mitochondrial electron transport (NIH, ACS). Key therapeutic targets include enzymes like dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), ion transporters like PfATP4, and surface antigens involved in host cell invasion (Microbiology Journal, BioRxiv). Drugs such as chloroquine, artemisinin, and atovaquone exert their effects by disrupting these vital protein-mediated pathways, though the rapid emergence of resistance—often mediated by mutations in genes like PfKelch13 or PfCRT—remains a significant therapeutic challenge (Microbiology Journal, MDPI). Understanding the structural and functional differences between these parasite proteins and their human homologs is essential for developing selective, low-toxicity treatments for malaria (NIH). Additionally, surface proteins like the circumsporozoite protein (CSP) are central to vaccine strategies aimed at blocking the parasite's entry into the liver (ResearchGate).

Other names

Malaria parasite proteinsPlasmodium falciparum proteinsPlasmodium antigensPlasmodium proteome

Inhibition of heme polymerase and heme detoxification (e.g., by chloroquine) (Microbiology Journal, NIH); inhibition of dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in the folate pathway (Microbiology Journal, BioRxiv); inhibition of the mitochondrial cytochrome bc1 complex (e.g., by atovaquone) (ACS, BioRxiv); inhibition of the PfATP4 sodium transporter (Microbiology Journal, BioRxiv); inhibition of protein synthesis via the 80S ribosome or elongation factor 2 (EF2) (NIH, BioRxiv); and induction of oxidative stress and protein alkylation by artemisinin derivatives (Microbiology Journal, MDPI).